EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Efficacy of doxycycline in treatment of Staphylococcus spp. prosthetic joint infections: a CRIOGO multicentre case–control study

Vincent Fiorenza, Romain Millot iD, Raphaël Lecomte iD, Hakim Essid, Marion Lacasse, Adrien Lemaignen, David Boutoille iD, Chloé Plouzeau-Jayle, Gwenaël Le Moal

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag219 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Vincent Fiorenza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, CHU de Poitiers Site de la Milétrie, Poitiers, France. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Doxycycline, Prosthesis-Related Infections, Staphylococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prosthetic joint infections (PJI) of the hip and knee are most often caused by Staphylococcus spp. and require long-term treatment with rifampicin and fluoroquinolone as first-line treatment. However, resistance, contraindications or intolerance highlight the need for effective oral alternatives. Tetracyclines, with favourable bioavailability and bone penetration, represent a potential option.

Methods

CYCLIOS, a multicentre retrospective matched case–control study, included adult patients with staphylococcal hip or knee PJI treated with curative intent. Cases received doxycycline as part of their antibiotic regimen, and controls were matched 1:2 on infection site, age, pathogen and date of multidisciplinary meeting. The primary endpoint was a composite of death or treatment failure at 2 years.

Results

Sixty-seven patients were analysed (23 doxycycline group, 44 control). The two groups were comparable except for immunosuppression (17% (4/23) versus 2% (1/44); P = 0.04). The median duration of doxycycline was 75 days (interquartile range [IQR]: 47–83). The primary endpoint occurred in 43% (10/23 and 19/44) of both groups (odds ratio [OR] 1.01, 95% confidence interval [CI] [0.36–2.84]; P = 0.98). Treatment-related adverse events were reported in 35% (8/23) versus 20% (9/44); P = 0.24, but premature discontinuation remained rare (4% (1/23) versus 5% (2/44); P = 1.00). In the conditional logistic regression model, doxycycline exposure was not associated with an increased risk of unfavourable outcome (univariate OR 1.06, 95% CI [0.40–2.81]; P = 0.91 and multivariate OR 0.97, 95% CI [0.23–4.25]; P = 0.97).

Conclusion

In this multicentre real-life study, doxycycline-based regimen, no significant difference was observed between doxycycline-based regimens and comparator strategies, with acceptable tolerability. Given the observational design and limited sample size, these findings should be considered exploratory. Tetracyclines may represent a pragmatic therapeutic alternative when first-line options are not feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDoxycyclineProsthesis-Related InfectionsStaphylococcal InfectionsStaphylococcusAgedAged, 80 and overFemaleHumansMaleMiddle AgedCase-Control StudiesRetrospective StudiesTreatment Outcome

Substanzen

Anti-Bacterial AgentsDoxycycline

Autor:innen und Institutionen

  • Department of Infectious Diseases, CHU de Poitiers Site de la Milétrie, Poitiers, France.
  • PHAR2, INSERM U107, Poitiers University, Poitiers, France.
  • Department of Infectious Diseases, CHU Hôtel-Dieu, Nantes, France.
  • Department of Infectious Diseases, CHU Bretonneau, Tours, France.
  • Bacteriology and Infection Control Laboratory, Infectious Agents Department, CHU de Poitiers Site de la Milétrie, Poitiers, France.

ORCID-Profile: Romain Millot, Raphaël Lecomte, David Boutoille

Zitieren

APA

Fiorenza, V., Millot, R., Lecomte, R., Essid, H., Lacasse, M., Lemaignen, A., Boutoille, D., Plouzeau-Jayle, C., & Moal, G. L. (2026). Efficacy of doxycycline in treatment of Staphylococcus spp. prosthetic joint infections: a CRIOGO multicentre case–control study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag219

Vancouver

Fiorenza V, Millot R, Lecomte R, Essid H, Lacasse M, Lemaignen A, et al. Efficacy of doxycycline in treatment of Staphylococcus spp. prosthetic joint infections: a CRIOGO multicentre case–control study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag219

BibTeX
@article{Fiorenza2026,
  author = {Fiorenza, Vincent and Millot, Romain and Lecomte, Raphaël and Essid, Hakim and Lacasse, Marion and Lemaignen, Adrien and Boutoille, David and Plouzeau-Jayle, Chloé and Moal, Gwenaël Le},
  title = {Efficacy of doxycycline in treatment of Staphylococcus spp. prosthetic joint infections: a CRIOGO multicentre case–control study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag219}
}
Kostenlos starten →